Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Malignant mesenchymal tumor 1Colorectal Neoplasms 1Carcinoma 1

Interventions

Radiotherapy 8Ifosfamide 7Filgrastim 7Vincristine 6Doxorubicin 6Dactinomycin 6Cyclophosphamide 6sargramostim 3Etoposide 3Radiotherapy, Conformal 2Irinotecan 2Imatinib Mesylate 2Granulocyte Colony-Stimulating Factor 2Epirubicin 2Chemotherapy, Adjuvant 2Carboplatin 2trioctyl phosphine oxide 1romidepsin 1pegfilgrastim 1indolepropanol phosphate 1etoposide phosphate 1cixutumumab 1Watchful Waiting 1Trabectedin 1Topotecan 1Sunitinib 1Radiation 1Peripheral Blood Stem Cell Transplantation 1Observation 1Neoadjuvant Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Malignant mesenchymal tumor × NHS-IL12 immunocytokine × Clear all
NCT01417546 2021-10-18

NHS-IL12 for Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
72 enrolled

Malignant mesenchymal tumor, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡